Apriori Bio

Apriori Bio is a Flagship Pioneering-founded biotech based in Cambridge, MA, established to transform vaccinology through predictive biology and AI. Its core technology, the Octavia platform, experimentally maps viral fitness landscapes to anticipate evolutionary pathways, enabling the design of vaccine antigens intended to elicit broader and more potent immune responses against both existing and future strains. The company is in a pre-clinical stage, building its pipeline against seasonal and pandemic respiratory viruses, and is led by a team with deep expertise in biotechnology, vaccinology, and computational science. Its strategy hinges on validating its predictive platform to create next-generation vaccines that could offer more durable and universal protection.

Octavia™, a biology-enabled AI/ML platform that predicts viral evolution by screening variant libraries against human sera to generate fitness maps, which are used to engineer optimized vaccine antigens designed to elicit broad and potent immune responses.

Apriori competes in the emerging field of computational vaccine design, facing companies like Vaxxinity, Gritstone bio, and academic efforts. Its key differentiator is the tight integration of proprietary biological data generation with AI/ML models. However, it ultimately competes with major pharma (Pfizer, Moderna, GSK, Sanofi) who are also investing in next-gen flu and COVID-19 vaccines and have immense R&D and commercial scale.